Scarica l'app Stockscreener
112.42
1.18%
-1.34
Pre-mercato:
112.41
-0.01
-0.01%
Precedente Chiudi:
$113.76
Aprire:
$113.57
Volume 24 ore:
853.71K
Relative Volume:
0.77
Capitalizzazione di mercato:
$6.46B
Reddito:
$360.35M
Utile/perdita netta:
$-149.57M
Rapporto P/E:
-37.98
EPS:
-2.96
Flusso di cassa netto:
$-81.27M
1 W Prestazione:
+3.40%
1M Prestazione:
+27.17%
6M Prestazione:
+12.63%
1 anno Prestazione:
-23.18%
Intervallo 1D:
$111.81
$115.82
Intervallo di 1 settimana:
$108.16
$115.82
Portata 52W:
$73.16
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Nome
Glaukos Corporation
Settore
Industria
Telefono
949-367-9600
Indirizzo
1 GLAUKOS WAY, ALISO VIEJO, CA
Confronta GKOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
112.42 | 6.53B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
126.71 | 220.59B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
94.48 | 137.79B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
352.58 | 134.49B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.30 | 125.28B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.84 | 49.51B | 5.88B | 1.34B | 799.60M | 2.3489 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Iniziato | Goldman | Buy |
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-12-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Iniziato | Truist | Buy |
| 2023-11-08 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-14 | Ripresa | Stephens | Overweight |
| 2022-10-04 | Iniziato | Needham | Buy |
| 2022-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2022-02-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2021-11-03 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-12-09 | Iniziato | Oppenheimer | Perform |
| 2020-11-17 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Iniziato | Jefferies | Hold |
| 2020-03-05 | Iniziato | Citigroup | Sell |
| 2020-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-12-12 | Downgrade | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Iniziato | BTIG Research | Neutral |
| 2018-08-30 | Iniziato | Berenberg | Hold |
| 2018-08-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Reiterato | Stifel | Hold |
| 2018-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Downgrade | Stifel | Buy → Hold |
| 2018-03-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-03-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2016-10-27 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Glaukos Corporation Borsa (GKOS) Ultime notizie
Glaukos breaks ground on high-tech facility in Alabama, eyes 150 jobs - Alabama Weather Network
Piper Sandler reiterates Overweight rating on Glaukos stock as 2026 top pick - Investing.com India
Glaukos Announces Participation in J.P. Morgan Healthcare Conference - BioSpace
Revenue per share of Glaukos Corp – GETTEX:6GJ - TradingView — Track All Markets
Glaukos (NYSE: GKOS) CEO reports new performance-based RSUs and options - Stock Titan
Glaukos (GKOS) President & COO earns 7,316 stock options after goals met - Stock Titan
Glaukos Corporation (NYSE: GKOS) discloses CFO earning 3,660 stock options - Stock Titan
Glaukos Corp (GKOS) CDO Earns 2,054 Performance-Based Shares in 2025 - Stock Titan
Stifel reiterates Buy rating on Glaukos stock, maintains $115 price target - Investing.com
Glaukos price target raised to $125 from $117 at Needham - MSN
Glaukos Corporation $GKOS Shares Purchased by Holocene Advisors LP - MarketBeat
Glaukos price target raised to $125 from $113 at Citi - MSN
Gilder Gagnon Howe & Co. LLC Decreases Position in Glaukos Corporation $GKOS - MarketBeat
Eventide Asset Management LLC Sells 70,181 Shares of Glaukos Corporation $GKOS - MarketBeat
Braidwell LP Has $62.33 Million Stake in Glaukos Corporation $GKOS - MarketBeat
Gilbert Kliman Sells 5,000 Shares of Glaukos (NYSE:GKOS) Stock - MarketBeat
Citigroup Maintains Glaukos (GKOS) Buy Recommendation - Nasdaq
Glaukos Corporation $GKOS Shares Bought by Osterweis Capital Management Inc. - MarketBeat
FDA approves Glaukos’ Epioxa as incision-free corneal disease treatment - MSN
GKOS: Citigroup Raises Glaukos Price Target to $125, Maintains B - GuruFocus
GLAUKOS Corp Director Sells 5,000 Shares - TradingView — Track All Markets
Glaukos (NYSE: GKOS) director exercises options and sells 5,000 shares - Stock Titan
Amundi Increases Holdings in Glaukos Corporation $GKOS - MarketBeat
Invesco Ltd. Sells 455,024 Shares of Glaukos Corporation $GKOS - MarketBeat
Glaukos Corporation $GKOS Shares Sold by Russell Investments Group Ltd. - MarketBeat
Glaukos stock price target raised to $125 from $117 at Needham By Investing.com - Investing.com South Africa
Glaukos Corporation (NYSE:GKOS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Dir Kliman Files To Sell 5,000 Of Glaukos Corp [GKOS] - TradingView — Track All Markets
Glaukos (GKOS) insider files to sell 5,000 common shares in $536K Rule 144 trade - Stock Titan
Needham Raises Price Target for GKOS, Maintains Buy Rating | GKO - GuruFocus
Trading the Move, Not the Narrative: (GKOS) Edition - news.stocktradersdaily.com
Needham Adjusts Glaukos Price Target to $125 From $117, Maintains Buy Rating - marketscreener.com
Glaukos stock price target raised to $125 from $117 at Needham - Investing.com Australia
Marshall Wace LLP Sells 114,086 Shares of Glaukos Corporation $GKOS - MarketBeat
Baird Financial Group Inc. Buys 9,545 Shares of Glaukos Corporation $GKOS - MarketBeat
Needham maintains Glaukos (GKOS) buy recommendation - MSN
Divisadero Street Capital Management LP Invests $10.51 Million in Glaukos Corporation $GKOS - MarketBeat
Glaukos (NYSE:GKOS) shareholders have earned a 34% CAGR over the last three years - Yahoo Finance
Glaukos Q1 2025 Earnings Preview - MSN
What market sentiment indicators show for Glaukos Corporation stockJuly 2025 Trends & Community Consensus Trade Alerts - Newser
Can Glaukos Corporation stock attract analyst upgradesJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - Newser
Norges Bank Takes $76.31 Million Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos Corporation $GKOS Shares Sold by Brown Capital Management LLC - MarketBeat
Glaukos Corporation Stock Analysis and ForecastMACD Trading Signals & Rapid Portfolio Expansion - earlytimes.in
Why Glaukos Corporation stock appears on watchlistsWeekly Trade Review & Daily Chart Pattern Signal Reports - Newser
Will Glaukos Corporation (6GJ) stock remain on Wall Street radarJuly 2025 EndofMonth & Precise Entry and Exit Recommendations - Newser
Can Glaukos Corporation (6GJ) stock double in coming yearsForecast Cut & Free Weekly Chart Analysis and Trade Guides - Newser
Is Glaukos Corporation stock a top hedge fund pick2025 Support & Resistance & Short-Term High Return Ideas - Newser
Transcript : Glaukos Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01 - marketscreener.com
Granite Investment Partners LLC Has $19.89 Million Stake in Glaukos Corporation $GKOS - MarketBeat
How higher bond yields impact Glaukos Corporation stockMarket Performance Report & High Accuracy Trade Alerts - Newser
Glaukos Corporation Azioni (GKOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):